NSE: INDOCO | BSE: 532612

Momentum Trap

Download real time

324.80 1.25 (0.39%)

70.95% Gain from 52W Low

59,595 NSE+BSE Volume

NSE 21 Jul, 2025 11:58 AM (IST)

2,996.2

Market Cap

Above industry Median

0.8

Beta 1Year

Very Low volatility

Board Meeting

The next board meeting for Indoco Remedies Ltd. is on 24 Jul 2025 for the purpose of Quarterly Results See details

Indoco Remedies Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for INDOCO, BSE:532612 Indoco Remedies Ltd.

Indoco Remedies Ltd.

30 Oct 2019

324.80

0.39%

Q2FY20 Result Update

Hold: Indoco Remedies Ltd.

Recommendation Target

Prabhudas Lilladhar

overall increase in exports by 40% YoY in Q2FY20 as UK sales gradually ramping up post re-instating GMP compliance by UK MHRA. The plant related manufacturing issues (mainly delay in re-approval of Goa Unit-2 by UK MHRA) are guided to have resolution in near to medium term. Exports in nonregulated markets increased by 36% with the benefits of lower base YoY. While management achieved US FDA resolutions in Goa Unit-2 and 3, as well as...

Indoco Remedies Ltd. has gained 35.41% in the last 3 Months

Indoco Remedies Ltd.

31 Jan 2019

324.80

0.39%

Indoco Remedies

Hold: Indoco Remedies Ltd.

Target

ICICI Securities Limited

Domestic formulations (~57% of FY18 revenues) have grown at 9% CAGR in FY13-18. The subdued growth can be attributed to high concentration of acute therapies that account for ~80% of overall formulations. With a market share of ~0.7% and overall rank of 31, the company is still a marginal player with some top brands in smaller categories like stomatologicals. However, with a positive outcome of restructuring exercise and improvement in MR productivity, we expect FY20E Indian formulations to deliver ~9% growth in FY18-20E to | 706 crore....

Indoco Remedies Ltd. is trading above all available SMAs

Indoco Remedies Ltd.

30 Jan 2019

324.80

0.39%

Q3FY19 Result Update - Big miss continues; Guidance projects quandary

Sell: Indoco Remedies Ltd.

Target

Prabhudas Lilladhar

Net sales, adj. EBITDA and PAT all miss estimates by big margin. India Change in Estimates | Target | Reco normalized base (as it grew only 8% YoY in Q3FY18). The sales in regulated...

Indoco Remedies Ltd. has an average target of 320.00 from 2 brokers.

Indoco Remedies Ltd.

16 Nov 2018

324.80

0.39%

Indoco Remedies

Hold: Indoco Remedies Ltd.

Target

ICICI Securities Limited

Q2FY19 numbers were substantially lower than I-direct estimates on all fronts. Revenues de-grew 17.3% YoY to | 235.6 crore (I-direct estimate: | 262.9 crore). Domestic formulations declined 15.5% to | 159 crore (I-direct estimate: | 169.4 crore) led by the high base of restocking post GST implementation. Export business declined 28.9% to | 52.8 crore (I-direct estimate: | 70.2 crore) EBITDA margins were at 5% against 14.5% in Q2FY18 (I-direct estimate of 14.5%) due to negative operational leverage. EBITDA...

Indoco Remedies Ltd. has gained 35.41% in the last 3 Months

Indoco Remedies Ltd.

16 Aug 2018

324.80

0.39%

Indoco Remedies

Hold: Indoco Remedies Ltd.

ICICI Securities Limited

Revenues grew 4.1% YoY to | 217.5 crore (I-direct estimate: | 277.1 crore). The 50.1% YoY growth in domestic formulations to | 149.7 crore (I-direct estimate: | 159.5 crore), led by lower base of GST impact in Q1FY18, was largely offset by 51.8% YoY decline in export formulations to | 41.4 crore (I-direct estimate: | 88.3 crore) EBITDA margins rose 470 bps YoY to 5.3% but lower than I-direct estimate of 15.8% mainly due to poor export formulations revenues Net loss fell 44.7% YoY to | 12.0 crore (I-direct net profit estimate:...

Indoco Remedies Ltd. is trading above all available SMAs

Indoco Remedies Ltd.

04 Jun 2018

324.80

0.39%

Indoco Remedies

Hold: Indoco Remedies Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues declined 2.6% YoY to | 270 crore (I-direct estimate: | 275 crore). Export formulations declined 17% YoY to | 88 crore (I-direct estimate: | 101 crore) while domestic formulations grew 16.1% to | 151 crore (I-direct estimate: | 154 crore) EBITDA margins increased 718 bps YoY to 18.9% (I-direct estimate of 14.0%) due to lower operational expenditure across line items. EBITDA rose 56.8% YoY to | 51 crore (I-direct estimate: | 39 crore)...

Indoco Remedies Ltd. has an average target of 320.00 from 2 brokers.

Indoco Remedies Ltd.

30 Jan 2018

324.80

0.39%

Indoco Remedies

Hold: Indoco Remedies Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues remained flat YoY at | 278 crore (I-direct estimate: | 296 crore). Miss vis--vis I-direct estimates was due to lower-thanexpected growth in domestic formulations, which grew 8% to | 156 crore (I-direct estimate: | 180 crore). Export formulations declined 8% to | 100 crore (I-direct estimate: | 94 crore) EBITDA margins improved 133 bps YoY to 15.5% (I-direct estimate of 14.8%) mainly on account of higher gross margins (67.5% in Q3FY18 vs. 64.7% in Q3FY17). EBITDA increased 9% YoY to | 43...

Indoco Remedies Ltd. has gained 35.41% in the last 3 Months

Is Indoco Remedies Ltd. worth buying?

60 Votes:

Buy 75.0%

Sell 15.0%

Hold 10.0%

RESEARCH REPORTS

Not Rated SEE REPORTS >

pdf

Accumulate SEE REPORTS >

pdf